6105-75-5

Basic information

• Product Name: 2-Methyl-1-morpholino-2-propanamine
• Synonyms: TIMTEC-BB SBB009721;4-(2-amino-2-methylpropyl)-morpholin;1,1-DIMETHYL-2-MORPHOLIN-4-YL-ETHYLAMINE;1,1-DIMETHYL-2-MORPHOLINOETHYLAMINE;2-METHYL-1-MORPHOLINO-2-PROPANAMINE;4-(2-AMINO-2-METHYL)PROPYLMORPHOLINE;4-MORPHOLINEETHANAMINE, ALPHA,ALPHA-DIMETHYL-;AKOS B025005
• CAS NO: 6105-75-5
• Molecular Formula: C₈H₁₈N₂O
• Molecular Weight: 158.24
• Mol File: 6105-75-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 227.6 °C at 760 mmHg
• Flash Point: 91.4 °C
• Appearance: /
• Density: 0.971 g/cm³
• Vapor Pressure: 0.077mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Methyl-1-morpholino-2-propanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-1-morpholino-2-propanamine(6105-75-5)
• EPA Substance Registry System: 2-Methyl-1-morpholino-2-propanamine(6105-75-5)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34
• Safety Statements: 23-26-36/37/39-45
• HazardClass: IRRITANT
• Hazardous Substances Data: 6105-75-5(Hazardous Substances Data)

Usage

General Description

2-Methyl-1-morpholino-2-propanamine is a chemical compound that is commonly used as a curing agent or hardener for epoxy resins. It is a clear, colorless to pale yellow liquid with a strong amine odor. This chemical is known for its ability to improve the chemical and physical properties of epoxy resins, making them more resistant to heat, chemicals, and mechanical stress. It is also used in the production of waterborne epoxy coatings and adhesives, as well as in the formulation of high-performance composites and electrical insulating materials. Additionally, 2-Methyl-1-morpholino-2-propanamine is used in the pharmaceutical industry as a precursor in the synthesis of various drugs. However, it is important to handle and use this chemical with care, as it can be irritating to the skin, eyes, and respiratory system.

InChI:InChI=1/C8H18N2O/c1-8(2,9)7-10-3-5-11-6-4-10/h3-7,9H2,1-2H3

Upstream product

• 110-91-8 morpholine 
• 2658-24-4 2,2-dimethylaziridine 
• 33453-98-4 4-(2-methyl-2-nitropropyl)morpholine 

Downstream Products

• 1265633-81-5 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(2-methyl-1-morpholinopropan-2-yl)-1H-pyrazole-3-carboxamide 
• 931126-97-5 N-(2-methyl-1-morpholinopropan-2-yl)-2-(pyridin-3-ylmethylthio)benzamide 

Relevant articles and documents

Polycyclic derivatives and preparation thereof

The invention discloses compounds shown as a formula (I) and a formula (II) and stereoisomers, pharmaceutically acceptable salts, solvates, hydrates, N-oxides and prodrugs thereof, pharmaceutical compositions and preparation methods of the compounds and t

COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION

The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Storage stable perfusion solution for dihydropteridinones

Disclosed are storage stable aqueous infusible or injectable solutions containing an active substance of general formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients suitable for parenteral administration, and a process for preparing the infusible or injectable solutions according to the invention.